AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02587663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo breast conserving surgery
Study NCT02587663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Undergo bilateral whole-breast ultrasound
Study NCT02587663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonography
Description: Undergo targeted breast ultrasound
Study NCT02587663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Undergo targeted breast ultrasound
Study NCT02209636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Table identical to lanthanum carbonate but with no active ingredient
Study NCT02209636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Intravenous administration during measurement of flow mediated dilation.
Study NCT02209636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ascorbic Acid
Description: Intravenous administration during measurement of flow mediated dilation.
Study NCT03869827 — intervention group
Intervention type: OTHER
Intervention: necrotizing enterocolitis
Description: Collection of necrotizing enterocolitis diagnosis, as well as its severity, are based on the classification of Belle modified in 3 stages: 1) Suspected, 2) Proven, 3) Advanced
Study NCT02042131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Crisis Response Plan (S-CRP)
Study NCT02042131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Crisis Response Plan (E-CRP)
Study NCT02587663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Contrast agent used in MRI
Study NCT00603499 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium chloride
Description: Subjects in the intervention group received 2.5 gr of MgCl2 daily during 4 months, from a solution solution containing 50 gr of MgCl2 by 1000 ml.
Study NCT00603499 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in the control group received inert placebo once per day during 4 months
Study NCT02584608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTIMMUNE
Study NCT03587545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic nasal spray
Description: Total daily nasal administration of 2\*10\^8 CFU of probiotic bacteria delivered via 2 servings.
Study NCT03587545 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: Two servings of nasal administration of placebo nasal spray (not containing probiotic bacteria)
Study NCT01580371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-581
Description: CKD-581 qd for Day 1, 8 and 15 every 28days/Cycle
Study NCT02942576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects.
Study NCT02942576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VKA-Based Regimen
Description: Dosed at International Normalised Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in Canada, Italy, Poland, Hungary, Czech Republic, United Kingdom (UK), Taiwan and Korea.
Study NCT02942576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VKA-Based Regimen
Description: Dosed at INR levels. Standard of Care treatment in Germany, Belgium, and the Netherlands.
Study NCT02942576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VKA-Based Regimen
Description: Dosed at INR levels. Standard of Care treatment in France.
Study NCT02942576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VKA-Based Regimen
Description: Dosed at INR levels. Standard of Care treatment in Spain.
Study NCT04473482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Michigan Alcohol Improvement Network-Alcohol Reduction and Treatment tool
Description: The intervention corrects misconceptions about alcohol use, liver disease, and alcohol treatment and matches patients to their top three choices of treatment while providing them with brief explanations of each treatment option.
Study NCT03007069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mineralized plasmatic matrix (MPM).
Description: By using venoud blood from the patient, together with bone graft, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM, for 10 minutes , Which will result if sticky bone graft consistency after mixing.
Study NCT03007069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autogenous bone graft (gold standard).
Description: Exposed implant threads are to be covered with autogenous bone and collagen membrane.
Study NCT02943902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV10 ) 1+1, 6 weeks
Description: PCV10 1+1, 6 weeks \& 9 months
Study NCT02943902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV10 ) 1+1, 14 weeks
Description: PCV10 1+1, 14 weeks \& 9 months
Study NCT02943902 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate vaccine (PCV10 ) 2+1
Description: PCV10 2+1, 6\&14 weeks \& 9 months
Study NCT02943902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV13 ) 1+1, 6 weeks
Description: PCV13 1+1, 6 weeks \& 9 months
Study NCT02943902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV13 ) 1+1, 14 weeks
Description: PCV13 1+1, 14 weeks \& 9 months
Study NCT02943902 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate vaccine (PCV13 ) 2+1
Description: PCV13 2+1, 6\&14 weeks \& 9 months
Study NCT01124266 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard of care colonoscopy
Description: Single inspection by endoscopist during colonoscopy
Study NCT01124266 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard of care colonoscopy
Description: Dual inspection by both endoscopist and nurse during colonoscopy
Study NCT03632720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine
Description: Pharmaceutical form: solution for injection; route of administration: intramuscular, 0.5 mL
Study NCT03632720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal group B vaccine
Description: Pharmaceutical form: suspension for injection; route of administration: deep intramuscular, 0.5 mL
Study NCT03632720 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal group B vaccine
Description: Pharmaceutical form: suspension for injection; route of administration: deep intramuscular, 0.5 mL
Study NCT03632720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine
Description: Pharmaceutical form: powder and suspension for suspension injection; route of administration: deep intramuscular, 0.5 mL
Study NCT03632720 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine
Description: Pharmaceutical form: powder and suspension for suspension injection; route of administration: deep intramuscular, 0.5 mL
Study NCT03632720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human rotavirus RIX4414 strain vaccine
Description: Pharmaceutical form: oral suspension; route of administration: oral, 1.5 mL
Study NCT03632720 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human rotavirus RIX4414 strain vaccine
Description: Pharmaceutical form: oral suspension; route of administration: oral, 1.5 mL
Study NCT03632720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent polysaccharide conjugate vaccine
Description: Pharmaceutical form: suspension for injection; route of administration: intramuscular, 0.5 mL
Study NCT02209636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: Drug that is administered under the tongue that relaxes blood vessels. To be administered during measurement of flow mediated dilation.
Study NCT03632720 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal 13-valent polysaccharide conjugate vaccine
Description: Pharmaceutical form: suspension for injection; route of administration: intramuscular, 0.5 mL
Study NCT01528852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 4%
Description: 4% liquid solution used for cord cleaning once daily for 10 days
Study NCT01528852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 4%
Description: Chlorhexidine 4% liquid solution used for cord cleaning once daily for 10 days
Study NCT01528852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control cord cleaning solution
Description: Mild soapy solution used to clean cord once daily for 10 days
Study NCT01290354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Unlabelled, administered orally
Study NCT01290354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C] lapatinib
Description: Radiolabelled, administered intravenously
Study NCT04902144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Medical data collected
Study NCT04902144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT04902144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Receive coaching
Study NCT05237635 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: descriptive case-scenarios
Description: Each case-scenario will include: (1) a GRADE Summary of Finding (SoF) table providing information about the Population, Intervention, Comparator, Outcome (PICO), the relative and absolute anticipated effects of the intervention, and the certainty in the evidence; (2) a Health Outcome Descriptor describing key attributes of the outcome under consideration including symptoms, time horizon, testing and treatment, and consequences; a measure of the impact on health of the outcome (also known as 'value' of the outcome or 'health utility' in health economics).
Study NCT05237635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: descriptive case-scenarios
Description: Each case-scenario will include: (1) a GRADE Summary of Finding (SoF) table providing information about the Population, Intervention, Comparator, Outcome (PICO), the relative and absolute anticipated effects of the intervention, and the certainty in the evidence; (2) a Health Outcome Descriptor describing key attributes of the outcome under consideration including symptoms, time horizon, testing and treatment, and consequences; a measure of the impact on health of the outcome (also known as 'value' of the outcome or 'health utility' in health economics).
Study NCT00216736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Single dose oral dexamethasone 8mg at time of ED discharge
Study NCT00216736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single dose oral placebo at ED discharge
Study NCT02282722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational informed consent for chemotherapy
Description: Investigational informed consent materials consist of regimen-specific multimedia tools: a video plus a booklet.
Study NCT02282722 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual, standard-of-care informed consent for chemotherapy
Description: The enrolling site's institutional standard-of-care informed consent materials.
Study NCT02081105 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PEEP of 5 or 15 cm H2O
Description: PEEP of 5 or 15 cm H2O set at the respirator and applied to the patient for 10 minutes. Then, measurements are made at each PEEP in the following order: arterial blood gas, CXR, pressure-volume curve.
Study NCT02575651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib either at 10,20,40,80,120mg ....., capsule oral.
Study NCT04516460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interventional arm: endoscopic resection plus PuraStat®
Description: Interventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to prevent bleeding after endoscopic resection of colorectal neoplastic lesions
Study NCT04692558 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HYALURONIC ACID
Description: Hyaluronic acid will be applied on denuded root surface after reflection of isolated gingival recession.
Study NCT04692558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronally advanved flap with connective tissue harvesting
Description: Coronally advanced flap surgery with connective tissue harvesting from palate
Study NCT04692558 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronally advanved flap with connective tissue harvesting
Description: Coronally advanced flap surgery with connective tissue harvesting from palate
Study NCT02541227 — intervention group
Intervention type: DRUG
Intervention: Cerebrolysin
Description: Cerebrolysin dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
Study NCT00721435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D Tomosynthesis and ultrasound imaging
Description: 3D tomosynthesis \& ultrasound imaging for scanning masses or healthy breast tissue
Study NCT03822754 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV-bOPV-bOPV vaccination schedule
Description: Single intramuscular injection of the experimental sIPV (0.5 ml) on Day 0, following two doses of bOPV (0.1 ml) on Day 30 and Day 60 respectively. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by Sinovac Vaccine Technology Co., Ltd. The poliovirus (Live) vaccine type I \& type III (Human Dipoid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
Study NCT03822754 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: wIPV-bOPV-bOPV vaccination schedule
Description: Single intramuscular injection of the control wIPV (0.5 ml) on Day 0, following two doses of bOPV (0.1 ml) on Day 30 and Day 60 respectively.The control wild strain inactivated poliovirus vaccine (wIPV) was manufactured by SANOFI PASTEUR S.A. The poliovirus (Live) vaccine type I \& type III (Human Dipoid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
Study NCT04255797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: baby massage
Description: The steps are as follows:1. Monitor the physiological indicators before massage, 2. Assist premature babies to lie on prone, take off their clothes and diapers, and then apply the baby's massage oil to the hands of both parents to warm them. 3. In the incubator, slight pressure touch the baby's body with warm palms and fingers.
Study NCT04199598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abediterol (2.4 μg)
Description: 2.4 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser
Study NCT04199598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abediterol (4.8 μg)
Description: 4.8 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser
Study NCT04199598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abediterol (2.4 μg)
Description: 2.4 μg (delivered dose) abediterol via OMRON NE-C900-E nebuliser
Study NCT04199598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abediterol (2.5 μg)
Description: 2.5 μg (nominal dose) abediterol via DPI, reference
Study NCT02893735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Charisma-Diamond
Description: The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Charisma-Diamond in combination Gluma2 Bond etch\&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
Study NCT02893735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Filtek-Z550
Description: The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Filtek-Z550 in combination with Adper™ Single Bond 2 etch\&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
Study NCT01222234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol - CKD
Description: Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
Study NCT01222234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calcitriol - CKD
Description: Calcitriol 0.25 mcg once daily for 8 weeks
Study NCT01222234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol - non-CKD
Description: Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
Study NCT03342339 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cognitive examination
Description: mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test
Study NCT03342339 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: viewing of video
Description: viewing during 5 minutes scale of differential emotions and Positive and Negative Affect Scale
Study NCT02209636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitroglycerin
Description: Drug that is administered under the tongue that relaxes blood vessels. To be administered during measurement of flow mediated dilation.
Study NCT02209636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation measurement
Description: Measurement of the blood flow in the brachial artery, an artery in the upper arm, using ultrasound.
Study NCT02209636 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Flow-mediated dilation measurement
Description: Measurement of the blood flow in the brachial artery, an artery in the upper arm, using ultrasound.
Study NCT03141645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid loading
Description: Patients in the preoperative intravenous fluid loading group (group F) will receive ringer lactate solution 10ml/kg in 15 minutes before starting operation.
Study NCT03141645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Patients in the ondansetron group (group O) will receive an 8 mg of intravenous ondansetron in 15 minutes before finishing operation
Study NCT00600860 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: Only registration of clinical practice
Study NCT02586402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegol-Sihematide
Study NCT02586402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Study NCT00711074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: single dose 200mg aqueous solution
Study NCT04157556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yo-Yo Intermittent Recovery Test Level 1
Description: The test is a standard test battery with progressively increasing speeds. After every 40-m run (2x20 m), active rest is performed by walking or jogging at a distance of 10 m (2x5 m). for 10 seconds. Participants are trying to adjust their speed according to incoming audio signals.The test is terminated when the participants can not reach the signal twice. The test ends in 10-20 minutes depending on the level of participants.~Reference Bangsbo, J., Iaia, F. M., \& Krustrup, P. (2008). The Yo-Yo intermittent recovery test. Sports medicine, 38(1), 37-51.~Krustrup, P., Mohr, M., Amstrup, T., Rysgaard, T., Johansen, J., Steensberg, A., ... \& Bangsbo, J. (2003). The yo-yo intermittent recovery test: physiological response, reliability, and validity. Medicine \& Science in Sports \& Exercise, 35(4), 697-705.
Study NCT02718300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Up to 3 oral once a day (QD) doses of parsaclisib. Doses will be taken once daily for 8 weeks, followed by once weekly dosing at the same dose level.